Abiopharma

Lineage Cell Therapeutics Initiates Cell Transplant Program In Type 1 Diabetes

First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity

Immutep Announces Data from EFTISARC-NEO Phase II Evaluating Neoadjuvant Efti in Soft Tissue Sarcoma Accepted for Oral Presentation at CTOS 2025

New Form 8-K - Summit Therapeutics Inc. Filed: 2025-09-08 AccNo: 0001599298-25-000137 Size: 5 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Aprea Therapeutics, Inc. Filed: 2025-09-08 AccNo: 0001558370-25-011909 Size: 4 MB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

Curaleaf Joins S&P/TSX Composite Index

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

New Form 6-K - ONCOLYTICS BIOTECH INC Filed: 2025-09-08 AccNo: 0001129928-25-000074 Size: 36 KB

Cybin - Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

Cybin Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder

New Form 6-K - GSK plc Filed: 2025-09-08 AccNo: 0001654954-25-010455 Size: 6 MB

New Form 8-K - Clearside Biomedical, Inc. Filed: 2025-09-08 AccNo: 0000950170-25-113362 Size: 154 KB Item 1.01: Entry into a Material Definitive Agreement

A New Press Release from Oncolytics Biotech, Inc

Cordova Ashley 🟢 acquired 81.5K shares of NovoCure Ltd (NVCR) at $12.22 Transaction Date: Sep 05, 2025 | Filing ID: 006130

New Form 4/A - CorMedix Inc. Filed: 2025-09-08 AccNo: 0001213900-25-085282 Size: 5 KB